Carboplatin vs Etoposide and Cisplatin for Advanced Seminoma
Author Information
Author(s): Horwich A, Oliver R T D, Wilkinson P M, Mead G M, Harland S J, Cullen M H, Roberts J T, Fossa S D, Dearnaley D P, Lallemand E, Stenning S P
Primary Institution: MRC Cancer Trials Office
Hypothesis
The use of single agent carboplatin is expected to be associated with reduced toxicity compared to a standard combination of etoposide and cisplatin.
Conclusion
The trial did not show statistically significant differences in survival outcomes between single agent carboplatin and the combination therapy.
Supporting Evidence
- 130 patients were randomly assigned to treatment groups.
- The estimated 3-year progression-free survival rate was 71% for carboplatin and 81% for etoposide + cisplatin.
- The trial closed early due to recommendations from an independent data monitoring committee.
- At a median follow-up of 4.5 years, 81% of patients had been followed for at least 3 years.
Takeaway
Doctors wanted to see if a simpler chemotherapy drug, carboplatin, was as good as a stronger mix of drugs for treating a type of cancer called seminoma, but they found no clear winner.
Methodology
Patients were randomly assigned to receive either carboplatin or a combination of etoposide and cisplatin, with follow-up for progression-free survival and overall survival.
Limitations
The trial was limited in size, which affected its ability to conclusively determine equivalence in treatment outcomes.
Participant Demographics
Patients with advanced seminoma.
Statistical Information
P-Value
0.21
Confidence Interval
95% CI for PFS: 60–82% for carboplatin, 71–90% for etoposide + cisplatin.
Statistical Significance
p=0.21
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website